Your SlideShare is downloading. ×
Corporate Presentation
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Corporate Presentation


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. Revolutionizing Vaccines Dr. J. Joseph Kim President & CEO NYSE MKT: INO
  • 2. Forward Looking Statement Our commentary and responses to your questions may contain forward-looking statements, including comments concerning clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Inovio’s technology by potential corporate partners, capital market conditions, timing of events, cash consumption and other subjects. Information concerning factors that could cause actual results to differ materially from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended September 30, 2013 and other regulatory filings from time to time. 2
  • 3. Inovio: Global Leader in Active Immune Therapy 2013: Dynamic Year • Best T cell responses in published clinical studies • Validating license deal with Roche in 2013 • $10 mm up-front, all development costs, $412.5 mm in milestones, plus royalties 2014: Transformative Year • Phase II efficacy data from lead drug mid-year • More cancer trials starting (cervical, head & neck, prostate, breast, lung) • Additional pharma deals in the works 3
  • 4. Empowering Our Own Immune System to Defeat Disease 4
  • 5. T cells: Inovio Commands the Body’s SWAT Team Target cell • Key player in effective immune therapy • Kills tumors and infected cells • Are safe and tolerable • Requires a directive to attack T cell Cytotoxic T lymphocyte 5
  • 6. T cells: Inovio Commands the Body’s SWAT Team Target cell T cell Cytotoxic T lymphocyte 6 Provided by Dr. Philip Greenberg Hutchinson Cancer Research Center
  • 7. Recent PD-1 Clinical Data Validation: T cells All-Important in Immune Therapy 7
  • 8. Passive Immune Therapy: Checkpoint Inhibitors Passive T cell PD-1 PD-L1 8 Cancer cell
  • 9. Passive Immune Therapy: Checkpoint Inhibitors T cell Validation of Inovio’s aggressive T cell therapy PD-1 Checkpoint inhibitor 9 PD-1 Therapy PD-L1
  • 10. Active Immune Therapy: Inovio Therapeutic Vaccines Active 10 Best-in-class T cells with powerful killing effect
  • 11. Active Immune Therapy: Inovio Therapeutic Vaccines 11 T cells are the key to clinical outcome
  • 12. Inovio: Leader in Active Cancer Immunotherapies • Efficacy can be improved by combining with active cancer vaccines • Inovio cancer vaccines: Potential to increase efficacy • Cervical/head & neck cancers • Breast cancer • Lung cancer • Pancreatic cancer • Melanoma • Prostate cancer • Concerns about safety and tolerability signals • Potential to improve safety and tolerability • Projected to be a $24 billion 12 market • Major products in multi-billion market • Unprecedented efficacy • Melanoma • Lung cancer • Others
  • 13. Powerful Combination of Active and Passive Immune Therapy 13
  • 14. Inovio’s Technology Inovio’s Technology • Synthetic DNA vaccines highly optimized for antigen expression • SynCon® sequences designed to break tolerance or provide universal protection Plasmids • CELLECTRA® electroporation ideal delivery of DNA vaccines • Best-in-class immune responses • Favorable safety profile Electroporation device 14 • Over 400 patents
  • 15. #1 in Generating and Driving T Cell Responses in People 15
  • 16. VGX-3100:Demonstrated Data In Class T cell Responses VGX-3100 Phase I Study Best • Strong T-cell response in 14 of 18 (78%) vaccinated subjects at month 4 • 83% response rate in highest dose group 16 *Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012 Oct; 4:155ra13. dOI:10.1126/scitranslmed.3004414
  • 17. Durable T cell Responses and T Cell Killing Effects • • 17 9 month durability of robust T cell response in 12/14 responders • 10/11 responders showed killing effect against target cells Safe & well tolerated Source: Science Translational Medicine Oct. 2012
  • 18. PENNVAX® HIV Vaccine: Highest CD8+ T cell Responses A: 3X vaccination without EP B: 4X vaccination without EP C: 2x vaccination with EP (month 2) D: 3x vaccination with EP (month 4) E: Memory response (month 9) A B Ref: Kalams et al JID 2013 18 C D E
  • 19. Broad Medical and Market Opportunities Product Name Indication Preclinical Vgx-3100 Therapeutic INO-3112 Cervical Cancer Therapeutic INO-3112 Head & Neck Cancer Therapeutic Ino-5150 Prostate cancer Therapeutic Ino-1400 Breast/lung cancers Therapeutic pennvax® hiv Preventive/Th erapeutic Ino-3510 influenza Preventive Ino-8000 Hepatitis C Therapeutic ino-1800 Hepatitis B Therapeutic Preventive MaV-12 19 Cervical dysplasia malaria Preventive INTERNALLY FUNDED EXTERNALLY FUNDED Phase I Phase II Phase III
  • 20. Inovio’s Lead Program VGX-3100: • Capitalizes on Inovio’s ability to generate T cells • Immunotherapy for pre-cancers and cancers caused by human papillomavirus (HPV) • Phase II on-going: high grade cervical pre-cancers (CIN 2/3 dysplasia) • Projected efficacy data: mid-2014 20
  • 21. Inovio’s Lead Program 21
  • 22. Inovio’s Lead Program 22
  • 23. Broad Medical and Market Opportunities HPV product franchise planning • CIN 2/3 phase III • Other HPV-related indications (cervical cancer and head/neck cancer): initiate phase II studies • Orphan designation potential 23
  • 24. INO-1400: Potential Universal Cancer Therapy 24 Yan J et al., Cancer Immunol Res. (2013)
  • 25. Broad Base of Support for Inovio Almost $60M in non-dilutive funding since 2009 25
  • 26. Power of our People 26 • Management • Board of Directors • Scientific Advisory Board
  • 27. Management J.Joseph Kim, PhD President & CEO • Decades of biotechnology/pharma management • Merck: hepatitis A and B vaccines manufacturing; HIV vaccine (Ad5) R&D Niranjan Y. Sardesai, PhD COO • Extensive biotech management and product development experience • Led development of diagnostics for mesothelioma, bladder cancer, and ovarian cancer for Fujirebio Diagnostics 27 Peter Kies CFO • Ernst & Young • Experience with growth companies Louis Pasteur Mark L. Bagarazzi, MD CMO • Clinical research experience incl. Merck • Led clinical/regulatory for shingles and rotavirus vaccines; DNA vaccine expert
  • 28. Board of Directors Morton Collins, PhD Avtar Dhillon, MD • General Partner, Battelle Ventures and Innovations Valley Partners Chairman, BOD • Former President & CEO, Inovio Biomedical J.Joseph Kim, PhD Simon X. Benito • Former Senior Vice President, Merck Vaccine Division Angel Cabrera, PhD • President, George Mason University • Former President, Thunderbird School of Global Management 28 Louis Pasteur • President & CEO, Inovio Adel Mahmoud, PhD • Professor, Princeton University • Former President, Merck Vaccines • Responsible for Gardasil®, Zostavax®, Proquad® and Rotateq®
  • 29. Scientific Advisory Board Philip Greenberg, MD David B. Weiner, PhD • Expert in T-cell immunology • Head, Immunology Program, Fred Hutchinson Cancer Research Center Chairman •“Father of DNA vaccines” • Dept. of Pathology & Laboratory Medicine, University of Pennsylvania Stanley A. Plotkin, MD Thomas S. Edgington, MD • Founded multiple biotech companies; extensively published • Emeritus Professor, Scripps Research Institute Anthony W. Ford-Hutchinson, PhD • Former SVP, Vaccines R&D, Merck • Oversaw development: Singulair®, Januvia®, Gardasil®, Zostavax®, Proquad® and Rotateq® 29 Louis Pasteur • Developed rubella and rabies vaccines • Oversaw Sanofi flu vaccine • Emeritus Professor, Wistar Institute & University of Pennsylvania
  • 30. Stock Price 2/1/13 30 3/1/13 4/1/13 5/1/13 6/1/13 7/1/13 8/1/13 9/1/13 10/1/13 11/1/13 12/1/13 1/1/14 2/1/14
  • 31. Financial Information NYSE MKT: INO Cash, cash equivalents & short-term investments1 $ 46.3 M Additional cash4 $ 11.1 M Debt1 0M Cash runway 1Q 2016 Issued & outstanding shares2 211.4 M Recent price3 $2.49 $526.4 M Market cap3 31 1Sep. 30, 2013 2Jan 31, 2014 3 Feb 3, 2014 4 Nov 12, 2013
  • 32. Upcoming Value Drivers 32
  • 33. Upcoming Value Drivers Vgx-3100 INO-3112 INO-3112 Ino-5150 Ino-1400 33 INTERNALLY FUNDED Cervical dysplasia Mid-2014 Phase II study data Cervical Cancer 1H 2014 Initiate phase I/IIa Head & Neck Cancer 1H 2014 Initiate phase I/IIa Prostate cancer 1H 2014 Initiate phase I/IIa Breast/lung Cancer EXTERNALLY FUNDED 2014 Initiate phase I/IIa
  • 34. Upcoming Value Drivers PennVAX Ino-1800 MAV-12 Ino-8000 34 INTERNALLY FUNDED HIV 2014 Initiate PENNVAX -GP phase I study Hepatitis B 2014 Prepare phase I/IIa Malaria 2014 Initiate phase I/IIa Hepatitis C 2015 Report phase I data EXTERNALLY FUNDED
  • 35. The Opportunity Investor Highlights • Break-through active immune therapy with the power to save lives and maximize shareholder value • Targeting broad range of diseases and billion dollar markets • Best-in-class T cells to prevent, treat & cure cancers and infectious diseases • Phase II efficacy data coming • Validating partnership with Roche with more deals in the works 35
  • 36. Investor Contact Investor Contact Bernie Hertel Senior Director, Communications & Investor Relations 858-410-3101  36